tbuckley/cabot-search huggingface dataset:
The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer
Authors: Matthew P. Smeltzer, Murry W. Wynes, Sylvie Lantuejoul, Ross Soo, Suresh S. Ramalingam, Marileila Varella-Garcia, Meghan Meadows Taylor, Kristin Richeimer, Kelsey Wood, Kristen E. Howell, Mercedes Lilana Dalurzo, Enriqueta Felip, Gina Hollenbeck, Keith Kerr, Edward S. Kim, Clarissa Mathias, Jose Pacheco, Pieter Postmus, Charles Powell, Masahiro Tsuboi, Ignacio I. Wistuba, Heather A. Wakelee, Chandra P. Belani, Giorgio V. Scagliotti, Fred R. Hirsch
Journal: Journal of Thoracic Oncology (2020)

IntroductionAccess to targeted therapies for lung cancer depends on the accurate identification of patients' biomarkers through molecular testing. The International Association for the Study of Lung Cancer (IASLC) conducted an international survey to evaluate perceptions on current practice and barriers to implementation of molecular testing.MethodsWe distributed the survey to IASLC members and other health care professionals around the world. The survey included a seven-question introduction for all respondents, who then answered according to one of three tracks: (1) requesting tests and treating patients, (2) performing and interpreting assays, or (3) tissue acquisition. Barriers to implementing molecular testing were provided in free-response fields. The chi-square test was used for regional comparisons.ResultsA total of 2537 respondents from 102 countries participated. Most respondents who test and treat patients believe that less than 50% of patients with lung cancer in their country receive molecular testing, but reported higher rates within their own practice. Although many results varied by region, the five most frequent barriers cited in all regions were cost, quality and standards, access, awareness, and turnaround time. Many respondents expressed dissatisfaction with the current state of molecular testing for lung cancer, including 41% of those performing and interpreting assays. Issues identified included trouble understanding results (37%) and the quality of the samples (23% reported >10% rejection rate). Despite concerns regarding the quality of testing, 47% in the performing and interpreting track stated there is no policy or strategy to improve quality in their country. In addition, 33% of respondents who request tests and treat patients were unaware of the most recent College of American Pathologists, IASLC, and Association for Molecular Pathology guidelines for molecular testing.ConclusionsAdoption of molecular testing for lung cancer is relatively low across the world. Barriers include cost, access, quality, turnaround time, and lack of awareness.
Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?
Authors: Boris Freidlin, Edward L. Korn
Journal: Journal of Clinical Oncology (2019)

Evaluation of new anticancer therapies in randomized clinical trials (RCTs) is typically based on comparing a new treatment with a standard one, using a time-to-event end point such as overall survival or progression-free survival (PFS). Although the statistical framework underlying the design of these RCTs is centered on formal testing of a treatment effect, methods for estimation (quantification) of the treatment benefit are also specified. Currently, log-rank statistical tests and/or proportional hazards models are commonly used for the trial design and primary analysis. These methods are optimized for treatment effects that do not change substantially over time (the proportional hazard assumption).

Introduction of immunotherapeutic agents with potentially delayed treatment effects has renewed interest in statistical methods that can better accommodate general departures from proportional hazards and, particularly, a delayed treatment effect. This has led to considerable attention in, and some controversy about, appropriate statistical methodology for comparing survival curves, as demonstrated by the comments and replies on trial reports1-24 and at a Duke–US Food and Drug Administration workshop25 that offered alternatives to the standard log-rank/hazard-ratio methodology. While these new methods could be useful, as outlined in comprehensive reviews,26-30 we offer a caution about some of these methods’ limitations in translating statistical evidence into clinical evidence, both for formal treatment-effect hypothesis testing and for estimation (when used for the primary analysis).
A necessary discussion after transmission of multidrug-resistant organisms through faecal microbiota transplantations
Authors: Ed J Kuijper, Jessica Allegretii, Peter Hawkey, Harry Sokol, Simon Goldenberg, Gianluca Ianiro, Antonio Gasbarrini, Patrizia Kump, Samuel P Costello, Josbert Keller, Maria J G T Vehreschild
Journal: The Lancet Infectious Diseases (2019)
Abstract 17855: Using High-Fidelity Simulations to Improve Nursing Staff Training in Managing Cardiac Arrhythmias
Authors: Yu-Chen Ku, Chin-Chou Huang, Suh-Ing Hsieh, Li-Ling Hsu
Journal: Circulation (2017)

Introduction: High-fidelity simulations are widely used for resuscitation training. However, whether they could improve nursing staff’s training in managing cardiac arrhythmias is still unknown. Th...
P1.16-05 Incidence and Outcome of Multiple Primary Cancers (MPC) in a Series of Lung Cancer (LC) Patients
Authors: S. Cedres, A. Hernando-Calvo, P. Iranzo, A. Callejo, N. Pardo Aranda, A. Navarro, A. Martinez-Marti, J.D. Assaf, J.M. Miquel, G. Rodriguez, V. Monton, A. Pedrola, C. Viaplana, C. Carbonell, M. Sanso, R. Dienstmann, R. Amat, A. Vivancos, E. Felip
Journal: Journal of Thoracic Oncology (2019)
Stress-Induced Cellular Clearance Is Mediated by the SNARE Protein ykt6 and Disrupted by α-Synuclein
Authors: Leah K. Cuddy, Willayat Y. Wani, Martino L. Morella, Caleb Pitcairn, Kotaro Tsutsumi, Kristina Fredriksen, Craig J. Justman, Tom N. Grammatopoulos, Nandkishore R. Belur, Friederike Zunke, Aarthi Subramanian, Amira Affaneh, Peter T. Lansbury, Joseph R. Mazzulli
Journal: Neuron (2019)
P2.18-05 Patients with ypN2 NSCLC After Neoadjuvant Chemotherapy Followed by Surgery Can Benefit from PORT – A Retrospective Study of SEER Database
Authors: Y. Bao, J. Kang, Y. Men, X. Sun, M. Yuan, M. Zhao, X. Yang, Z. Hui
Journal: Journal of Thoracic Oncology (2019)
P2.01-39 Serial Plasma ctDNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in T790M+ NSCLC
Authors: B. Liao, W. Hsu, J. Lee, C. Yang, T. Tsai, W. Liao, C. Ho, C. Lin, J. Shih, C. Yu, J. Yang
Journal: Journal of Thoracic Oncology (2019)
P1.14-37 Lung Cancer in Never-Smokers: A Nationwide Population Based Mapping of Targetable Alterations
Authors: A. Salomonsson, M. Jönsson, C. Reuterswärd, A. Behndig, B. Bergman, J. Botling, E. Brandén, H. Brunnström, L. De Petris, A. Hussein, M. Johansson, H. Koyi, K. Lamberg Lundström, R. Lewensohn, N. Monsef, C. Ortiz-Villalón, A. Patthey, A. Vikström, G. Wagenius, J. Staaf, M. Planck
Journal: Journal of Thoracic Oncology (2019)
MA21.02 Genomic Origin and EGFR-TKI Efficacy of Pulmonary Adenosquamous Carcinoma
Authors: G. Lin, C. Li, P. Li, W. Fang, H. Xu, Y. Gong, Z. Zhu, Y. Hu, W. Liang, Q. Chu, W. Zhong, L. Wu, H. Wang, Z. Wang, Z. Li, J. Lin, Y. Guan, X. Xia, X. Yi, Q. Miao, B. Wu, K. Jiang, X. Zheng, W. Zhu, X. Zheng, H. Peisha, X. Wenjin, D. Hu, L. Zhang, X. Fan, T. Mok, C. Huang
Journal: Journal of Thoracic Oncology (2019)
Probiotic treatment using a mix of three Lactobacillus strains for lumbar spine bone loss in postmenopausal women: a randomised, double-blind, placebo-controlled, multicentre trial
Authors: Per-Anders Jansson, Dan Curiac, Irini Lazou Ahrén, Fredrik Hansson, Titti Martinsson Niskanen, Klara Sjögren, Claes Ohlsson
Journal: The Lancet Rheumatology (2019)
P2.14-04 Clinical Validation of Large NGS Gene Panel Using Residual Specimen
Authors: T. Sakamoto, K. Arai, K. Yamane, Y. Hirayama, Y. Teruya, M. Yanai, N. Kinoshita, K. Yamaguchi, H. Makino, M. Kodani, T. Igishi, A. Yamasaki
Journal: Journal of Thoracic Oncology (2019)
Common head and neck cancer treatment pathways and associated costs in the U.S. commercial managed care population
Authors: F. Camacho, C. D. Mullins, V. Joish, J. Choi
Journal: Journal of Clinical Oncology (2009)

e17001 Background: For the treatment of head and neck cancer (HNC), different modalities (chemotherapy, radiation, surgery, or chemoradiotherapy) can be used either independently or in combination with others. Information regarding real-world treatment pattern is limited. The purpose of this study was to identify common treatment pathways and associated costs. Methods: The study was performed using data from a large U.S. commercial managed care claims database. Adult subjects (≥18) diagnosed with HNC between January 1, 2006, to December 31, 2006, (index-period) were identified based on a pre-selected ICD-9-CM codes. All subjects were HNC diagnosis-naïve 12 months prior to their index dates (first date of HNC diagnosis) and followed for 12 months post index date. Treatment modalities were identified based on the Healthcare Common Procedure Coding System used in the U.S. Pathways were constructed by reflecting time of and between modality administration claims. Results: 6,570 subjects were identified. The average age was 61 years (±14.9) and 44% (n = 2869) were female. Midwest (31%) and east (31%) region had a higher (p &lt; 0.01) representation, compared to south (20%) and west (18%). Only 2,257 subjects (34%) received some type of treatment modality and were categorized into 20 mutually exclusive treatment pathways. Of these, 82% (n = 1,843) received single modality, 18% (n = 398) received a combination of 2, and 0.7% (n = 16) received a combination of 3 modalities. Among single modality pathways, radiation (34%; n = 619) was most common, however, cheomoradiotherapy (26%; n = 485) had the highest average patient cost ($98,440). Within double modalities, radiation followed by chemotherapy (24%; n = 95) was most common, however, chemoradiotherapy followed by surgery (4%; n = 16) had the highest average cost ($146,374). Within triple modalities, surgery followed by radiation then chemotherapy (50%; n = 8) was most common and costly ($95,868). Conclusions: The most common treatment pathways one year post HNC diagnosis used a single modality; however, the average patient costs within multiple modalities were higher. Further study is required to investigate if these patterns are comparable to current guideline recommendation. [Table: see text]
FEV<sub>1</sub>:FVC Thresholds for Defining Chronic Obstructive Pulmonary Disease
Authors: Xiaoxia Han, Yilong Zhang
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P2.04-36 Immune Checkpoint Inhibition for Non-Small Cell Lung Cancer (NSCLC) in Patients with Pulmonary Tuberculosis or Hepatitis B
Authors: G. Chan, Y.Q. Huang, Y. Ang, W.Q. Chong, V. Muthu, A. Wong, R. Soo
Journal: Journal of Thoracic Oncology (2019)
P2.04-04 CITEseq Characterization in Early Stage NSCLC Patients Identifies Distinct Patterns of Immune Infiltrate
Authors: A. Leader, B. Maier, J. Grout, C. Chang, L. Walker, M. Davila, A. Lanksy, T. Marron, R. Flores, M.B. Beasley, H. Salmon, A. Rahman, E. Kenigsberg, M. Merad
Journal: Journal of Thoracic Oncology (2019)
Utility of FilmArrayⓇ ME panel for prompt Neisseria meningitidis detection in non-cerebrospinal fluid samples– A case report
Authors: Paloma García-Clemente, Juan José Menéndez-Suso, Iker Falces-Romero, Luis Escosa-García, Cristina Schüffelmann, Emilio Cendejas-Bueno
Journal: Journal of Infection (2019)
Composite Organ and Hematologic Response Model Risk Stratifies Patients with Light Chain Amyloidosis
Authors: Surbhi Sidana, Nidhi Tandon, Angela Dispenzieri, Morie A. Gertz, Francis K Buadi, Martha Q. Lacy, David Dingli, Amie Fonder, Suzanne R. Hayman, Miriam Hobbs, Wilson I Gonsalves, Yi L. Hwa, Prashant Kapoor, Robert A. Kyle, Nelson Leung, Ronald S. Go, John A Lust, Stephen J. Russell, Steven R. Zeldenrust, Moritz Binder, S. Vincent Rajkumar, Shaji K. Kumar
Journal: Blood (2017)
P2.04-63 Evaluation of Combined Biomarkers for Tumor Response to Immunotherapy (I/O) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: H. Ramdani, M. Falk, S. Schatz, M. Tiemann, L. Heukamp, E. Schuuring, H. Groen, F. Griesinger
Journal: Journal of Thoracic Oncology (2019)
P1.04-51 Treatment with Immune Checkpoint Inhibitors for Advanced NSCLC in Elderly and Frail Patients. A Real-Life Experience
Authors: K. Fuglsang Junker, G. Persson, J. Lykkegaard Andersen, J. Sørensen, S. Langer, M. Pøhl
Journal: Journal of Thoracic Oncology (2019)
Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group
Authors: Alan N. Barkun, Majid Almadi, Ernst J. Kuipers, Loren Laine, Joseph Sung, Frances Tse, Grigorios I. Leontiadis, Neena S. Abraham, Xavier Calvet, Francis K.L. Chan, James Douketis, Robert Enns, Ian M. Gralnek, Vipul Jairath, Dennis Jensen, James Lau, Gregory Y.H. Lip, Romaric Loffroy, Fauze Maluf-Filho, Andrew C. Meltzer, Nageshwar Reddy, John R. Saltzman, John K. Marshall, Marc Bardou
Journal: Annals of Internal Medicine (2019)

This update of the 2010 International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding (UGIB) refines previous important statements and presents new clinically relevant recommendations.An international multidisciplinary group of experts developed the recommendations. Data sources included evidence summarized in previous recommendations, as well as systematic reviews and trials identified from a series of literature searches of several electronic bibliographic databases from inception to April 2018. Using an iterative process, group members formulated key questions. Two methodologists prepared evidence profiles and assessed quality (certainty) of evidence relevant to the key questions according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Group members reviewed the evidence profiles and, using a consensus process, voted on recommendations and determined the strength of recommendations as strong or conditional.Preendoscopic management: The group suggests using a Glasgow Blatchford score of 1 or less to identify patients at very low risk for rebleeding, who may not require hospitalization. In patients without cardiovascular disease, the suggested hemoglobin threshold for blood transfusion is less than 80 g/L, with a higher threshold for those with cardiovascular disease. Endoscopic management: The group suggests that patients with acute UGIB undergo endoscopy within 24 hours of presentation. Thermocoagulation and sclerosant injection are recommended, and clips are suggested, for endoscopic therapy in patients with high-risk stigmata. Use of TC-325 (hemostatic powder) was suggested as temporizing therapy, but not as sole treatment, in patients with actively bleeding ulcers. Pharmacologic management: The group recommends that patients with bleeding ulcers with high-risk stigmata who have had successful endoscopic therapy receive high-dose proton-pump inhibitor (PPI) therapy (intravenous loading dose followed by continuous infusion) for 3 days. For these high-risk patients, continued oral PPI therapy is suggested twice daily through 14 days, then once daily for a total duration that depends on the nature of the bleeding lesion. Secondary prophylaxis: The group suggests PPI therapy for patients with previous ulcer bleeding who require antiplatelet or anticoagulant therapy for cardiovascular prophylaxis.
P1.13-10 Incidence of Hidden Extrathoracic Metastases and Unexpected Second Malignancies Detected by PET in Patients with Lung Cancer
Authors: B. García Cabo, C. Caupena Auledas, M. Martinez Palau, T. Pribic, R. Costa Solá, A. Navarro Rolon, A. Hernandez Biette, J. Sanz Santos, J.M. González González, M. Ysamat Marfá
Journal: Journal of Thoracic Oncology (2019)
P2.16-40 Acknowledging Social and Economic Inequities Experienced by Canada’s Inuit: Implications for Diagnosis and Treatment of Lung Cancer
Authors: C. Bornais, C. Roberts, P. Wheatley-Price, T. Asmis, G. Barton, G. Nicholas, E. Alie, T. Greene
Journal: Journal of Thoracic Oncology (2019)
P2.17-22 Retrospective Analysis of Spread Through Air Spaces and Other Features in Patients with Stage IA Adenocarcinoma by the 8th TNM Classification
Authors: K. Nakao, J. Nitadori, K. Kitano, K. Nagayama, A. Shinozaki-Ushiku, M. Sato, M. Fukayama, J. Nakajima
Journal: Journal of Thoracic Oncology (2019)
EP1.01-94 The Role of Neoadjuvant Chemo-Immunotherapy in Unresectable Non-Small Cell Lung Cancer
Authors: M. Oh, A. Davis, R. Lentz, N. Peterman, A. Robertson, R. Srivas, N. Lambert, T. Wilson, H. Tezcan, A. Bharat, Y.K. Chae
Journal: Journal of Thoracic Oncology (2019)
PL02.04 Blood MicroRNA and LDCT Reduce Unnecessary LDCT Repeats in Lung Cancer Screening: Results of Prospective BioMILD Trial
Authors: U. Pastorino, M. Boeri, S. Sestini, F. Sabia, M. Silva, P. Suatoni, C. Verri, A. Cantarutti, N. Sverzellati, G. Corrao, A. Marchianò, G. Sozzi
Journal: Journal of Thoracic Oncology (2019)
Fumarate Metabolic Signature for the Detection of Reed Syndrome in Humans
Authors: Ruth T. Casey, Mary A. McLean, Benjamin G. Challis, Terri P. McVeigh, Anne Y. Warren, Lee Mendil, Richard Houghton, Stefano De Sanctis, Vasilis Kosmoliaptsis, Richard N. Sandford, Ferdia A. Gallagher, Eamonn R. Maher
Journal: Clinical Cancer Research (2019)

Inherited pathogenic variants in genes encoding the metabolic enzymes succinate dehydrogenase (SDH) and fumarate hydratase predispose to tumor development through accumulation of oncometabolites (succinate and fumarate, respectively; ref. 1). Noninvasive
P1.06-09 Prophylactic Irradiation of Tracts in Patients with Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis
Authors: Y.Y. Soon, B. Vellayappan, C.N. Leong, W.Y. Koh, J. Tey, I.W.K. Tham
Journal: Journal of Thoracic Oncology (2019)
Premature mortality in children aged 6–9 years with neurological impairments in rural Kenya: a cohort study
Authors: Jonathan A Abuga, Symon M Kariuki, Samson M Kinyanjui, Michaël Boele Van Hensbroek, Charles RJC Newton
Journal: The Lancet Global Health (2019)

Neurological impairments might significantly contribute to reduced life expectancy in low-income and middle-income countries (LMICs). There are no empirical studies of premature mortality in children with neurological impairments in Africa. This study estimated the risk of premature mortality in children with neurological impairments and identified risk factors and causes of death.
A Single-Step, High-Dose Selection Scheme Reveals Distinct Mechanisms of Acquired Resistance to Oncogenic Kinase Inhibition in Cancer Cells
Authors: Kenneth J. Finn, Scott E. Martin, Jeff Settleman
Journal: Cancer Research (2019)

Abstract Despite the remarkable clinical efficacy demonstrated by molecularly targeted cancer therapeutics, the benefits are typically temporary due to the emergence of acquired drug resistance. This has spurred a massive effort by the cancer research community to identify mechanisms used by cancer cells to evade treatment. Among the various methodologies developed and employed to identify such mechanisms, the most commonly used approach has been to model acquired resistance by exposing cancer cells in culture to gradually increasing concentrations of drug over an extended period of time. Here, we employed a less commonly used variation on this approach, wherein resistant cells are selected by immediately exposing cancer cells to a continuous, high concentration of drug. Using this approach, we isolated clones representing three distinct mechanisms of resistance to inhibition of MET kinase activity from a single clonally derived cancer cell line. The emergent clones had acquired resistance through engagement of alternative receptor tyrosine kinases either through upregulation of FGF3 or HBEGF or increased MAPK signaling through an activating V600E mutation in BRAF. Importantly, these mechanisms were not identified using the conventional “ramp-up” approach in previous studies that employed the same cell line. These results suggest that the particular nature of the selection scheme employed in cell culture modeling studies can determine which potential resistance mechanisms are identified and which ones may be missed, highlighting the need for careful consideration of the specific approach used to model resistance in cultured cells. Significance: Through modeling resistance to MET kinase inhibition in cultured cancer cells using single-step, high-dose selection, these findings highlight that the specific nature of the selection protocol impacts which resistance mechanisms are identified. See related commentary by Floros et al., p. 25
OA13.05 NADIM Study: Updated Clinical Research and Outcomes
Authors: M. Provencio, E. Nadal, A. Insa, R. Garcia Campelo, J. Casal, M. Domine, M. Majem, D. Rodriguez-Abreu, A. Martinez-Marti, J. De Castro Carpeno, M. Cobo, G. López-Vivanco, E. Del Barco, R. Bernabe, N. Viñolas, I. Barneto, S. Viteri, P. Martin Martorell, M. Jove, V. Calvo De Juan, B. Massuti
Journal: Journal of Thoracic Oncology (2019)
Peroral pyloromyotomy for the treatment of infantile hypertrophic pyloric stenosis
Authors: Zu-Qiang Liu, Quan-Lin Li, Jiang-Bin Liu, Hai-Feng Liu, Hong Ye, Ying Fang, Ping-Hong Zhou
Journal: Endoscopy (2019)

Infantile hypertrophic pyloric stenosis (IHPS) is the most common condition requiring surgical treatment in infants [1]. Traditionally, the standard treatments are laparoscopic or open pyloromyotomy [2]. Here, we report on the use of peroral pyloromyotomy (POP), also called gastric peroral endoscopic myotomy (G-POEM), which has shown promising results in the treatment of adult gastroparesis [3], for a novel application, the treatment of IHPS.
OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3
Authors: F. Oezkan, K. He, D. Owen, M. Pietrzak, J.H. Cho, R. Kitzler, R. Pearson, V. Rusch, J. Chaft, R. Suh, J. Blasberg, K. Reckamp, D. Raz, P. Kneuertz, L. Fiorillo, E. Garon, A. Nicholas, A. Johnson, K. Schulze, J. Grindheim, R. Banchereau, S. Phan, P. Bunn, D. Kwiatkowski, B. Johnson, M. Kris, I. Wistuba, J. Lee, G. Lozanski, D. Carbone
Journal: Journal of Thoracic Oncology (2019)
Clare Gerada: A sense of belonging is vital for doctors
Authors: Clare Gerada
Journal: BMJ (2019)

In Malta, 21 September is a national holiday. It celebrates the country gaining independence from the United Kingdom in 1964. As well as being British I’m also Maltese, although I’ve never lived there, and in recent years (no doubt sparked by the trauma of Brexit) I’ve found myself identifying more with my heritage. I’ve obtained my Maltese passport and ID card and even gone as far as learning the language, an impossible mix of Arabic and Italian.

This Independence Day, I was surrounded by other Maltese people at a central London hotel owned …